Amneal Pharmaceuticals, Inc. (AMRX) — ESG & Values Scores

Environment story

Amneal demonstrates minimal disclosed environmental transparency. No Scope 1, 2, or 3 emissions data is published in available filings. No net-zero target year is stated. The company notes compliance with environmental laws but reports no significant capital expenditure requirements for environmental compliance, suggesting limited direct mitigation initiatives. Operations span India, Ireland, and the U.S., with manufacturing and API production facilities that likely carry material environmental footprints, particularly in India, but these remain unquantified. The absence of renewable energy percentage disclosure, supply-chain carbon accounting, or climate-related targets results in a below-average score. The company's statement that environmental compliance 'is not expected to have a material adverse effect' suggests a compliance-minimalist posture rather than proactive decarbonization.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Environmental Compliance Framework

Subject to federal, state, and local environmental laws governing air emissions, wastewater discharges, solid/hazardous waste disposal, and remediation. Undergoes periodic environmental compliance reviews by regulatory agencies.
PLI Scheme Participation (India)

Participates in India Production Linked Incentive Scheme for Pharmaceutical Sector, generating other operating income. May include indirect sustainability incentives tied to efficient manufacturing.

Social story

Amneal reports 8,500+ employees globally, with ~2,500 in the U.S. and >6,000 in India and Ireland. Turnover rate of 17.9% in 2025 is moderate for the pharmaceutical sector. The company launched AmNeev, a female workforce onboarding program (68 participants in 2025 across injectables, sterile manufacturing, and digital functions), and operates AmWell employee well-being programs. However, the 10-K does not disclose: CEO-to-median-worker pay ratio, workforce diversity percentages by gender/race/ethnicity, union standing, documented labor disputes, or supply-chain human-rights audits. No evidence of NLRB complaints, strikes, or union-suppression activities is stated. The company emphasizes 'inclusive, performance-oriented environment' but lacks quantified diversity metrics and pay-equity disclosures. Social score is limited by incomplete DEI data; initiatives appear authentic but transparency is insufficient.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

AmNeev Female Workforce Development

Onboarded ~68 female employees across injectables, sterile manufacturing, and digital academies in 2025. Targeted capability-building program.
AmWell Employee Well-Being Program

Multi-faceted approach including health/wellness resources, employee assistance programs, workplace safety, and competitive benefits by geography.
Amneal Listens Engagement

Global listening approach including engagement surveys and pulse checks to solicit employee feedback and inform workplace practices and organizational priorities.

Governance story

Amneal exhibits concerning governance concentration. As of 31 Dec 2025, the Amneal Group (original founders/owners) controlled ~48% of voting power and designated 5 of 10 board seats. While this does not constitute a dual-class structure post-Reorganization (November 2023), the founder-majority influence is substantial and limits other shareholders' control. Board independence is not explicitly disclosed in the filing; a 5-of-10 independent designation is insufficient without formal documentation. The 10-K does not disclose annual lobbying expenditures or detail any antitrust/consumer-protection regulatory proceedings beyond a broad opioids settlement ($96.7M charge in 2024). No evidence of climate-regulation deregulation lobbying or shareholder litigation blocking climate proposals is found. The company operates under restrictive debt covenants limiting financial flexibility. Governance score reflects concentrated founder control, incomplete board-independence transparency, and lack of detailed lobbying/regulatory-action disclosures.

Criticisms on file

Concentrated Founder Control: Amneal Group owns ~48% of voting stock and designates 5 of 10 board seats, limiting minority shareholder influence.
Source: AMRX 10-K, Item 1A Risk Factors and Item 5; Third Amended and Restated Stockholders Agreement.
Opioids Settlement: ~$96.7M charge (2024) for nationwide resolution of opioid litigation brought by political subdivisions and Native American tribes.
Source: AMRX 10-K, MD&A, (Credit) Charges Related to Legal Matters; Note 19 Commitments and Contingencies.

Disclosed initiatives

Post-Reorganization Corporate Governance Simplification

Eliminated umbrella partnership-C-corporation structure (November 2023), converting to traditional C-corporation whereby all stockholders hold interests directly through public company.

Simplified corporate governance and consolidated financial reporting; founder group retains substantial voting control.
Board Oversight of Cybersecurity

Audit Committee receives periodic cybersecurity updates from IT leadership, including incident reports, industry trends, and NIST Cybersecurity Framework alignment.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Amneal Pharmaceuticals, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Amneal Pharmaceuticals, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)